Recombinant expression of the β-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules

Huguette Albrecht, Monique Cosman, Maria Ngu-Schwemlein, Michele Corzett, Kena W. Curran, Cheryl Dolan, Xiangming Fang, Sally J. DeNardo, Gerald L Denardo, Rod Balhorn

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Selective high-affinity ligands (SHALs) were selected as substitutes for monoclonal antibodies (mAbs) to deliver radioisotopes to malignant tumors. Because a SHAL (5 KD) is considerably smaller in comparison to an antibody (150 KD), a significant therapeutic index (TI) enhancement for radioimmunotherapy (RIT) is anticipated. The antibody-antigen (Ab-Ag) model system chosen for the development of SHALs consists of Lym-1, a MAb with proven selectivity in non-Hodgkin's lymphoma (NHL) patients and its well-characterized Ag, the β subunit of HLA DR10. Whereas Lym-1 is readily available, the β subunit of HLA-DR10 is not. Native, heterodimeric (α and β subunits) HLA-DR10 can be purified from Raji cells, which are known to overexpress this Ag. Inconsistent homogeneity between preparations of HLA-DR10 solubilized in the presence of detergents prompted us to express a recombinant form of the β subunit of HLA-DR10 in Escherichia coli. Negligible production yields (≤50 μg/L) were achieved by the expression of the full-length protein in a soluble form. By contrast, yields of 240 mg/L were obtained by expressing only the extracellular domain (ED) of the β subunit of HLA-DR10 in an insoluble form (inclusion bodies). The recovery yield of refolded protein was 75%. Circular dichroism (CD) and Lym-1 binding studies indicated that the recombinant ED of the β subunit of HLA-DR10 was properly folded. Therefore, this recombinant protein can be used as a surrogate for native heterodimeric HLA DR10 for the in vitro selection of SHALs and related targeting molecules.

Original languageEnglish (US)
Pages (from-to)531-542
Number of pages12
JournalCancer Biotherapy and Radiopharmaceuticals
Volume22
Issue number4
DOIs
StatePublished - Aug 2007

Fingerprint

Lymphoma
Ligands
Protein Refolding
Radioimmunotherapy
HLA-DR10 antigen
Antibodies
Inclusion Bodies
Circular Dichroism
Recombinant Proteins
Radioisotopes
Detergents
Non-Hodgkin's Lymphoma
Monoclonal Antibodies
Escherichia coli
Antigens
Neoplasms
Proteins

Keywords

  • Antibody
  • HLA-DR
  • Lymphoma
  • Radioimmunotherapy
  • Radioisotope

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology
  • Cancer Research

Cite this

Albrecht, H., Cosman, M., Ngu-Schwemlein, M., Corzett, M., Curran, K. W., Dolan, C., ... Balhorn, R. (2007). Recombinant expression of the β-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules. Cancer Biotherapy and Radiopharmaceuticals, 22(4), 531-542. https://doi.org/10.1089/cbr.2007.375

Recombinant expression of the β-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules. / Albrecht, Huguette; Cosman, Monique; Ngu-Schwemlein, Maria; Corzett, Michele; Curran, Kena W.; Dolan, Cheryl; Fang, Xiangming; DeNardo, Sally J.; Denardo, Gerald L; Balhorn, Rod.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 22, No. 4, 08.2007, p. 531-542.

Research output: Contribution to journalArticle

Albrecht, H, Cosman, M, Ngu-Schwemlein, M, Corzett, M, Curran, KW, Dolan, C, Fang, X, DeNardo, SJ, Denardo, GL & Balhorn, R 2007, 'Recombinant expression of the β-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules', Cancer Biotherapy and Radiopharmaceuticals, vol. 22, no. 4, pp. 531-542. https://doi.org/10.1089/cbr.2007.375
Albrecht, Huguette ; Cosman, Monique ; Ngu-Schwemlein, Maria ; Corzett, Michele ; Curran, Kena W. ; Dolan, Cheryl ; Fang, Xiangming ; DeNardo, Sally J. ; Denardo, Gerald L ; Balhorn, Rod. / Recombinant expression of the β-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules. In: Cancer Biotherapy and Radiopharmaceuticals. 2007 ; Vol. 22, No. 4. pp. 531-542.
@article{0f681d98f91849998a48a078ea336dfc,
title = "Recombinant expression of the β-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules",
abstract = "Selective high-affinity ligands (SHALs) were selected as substitutes for monoclonal antibodies (mAbs) to deliver radioisotopes to malignant tumors. Because a SHAL (5 KD) is considerably smaller in comparison to an antibody (150 KD), a significant therapeutic index (TI) enhancement for radioimmunotherapy (RIT) is anticipated. The antibody-antigen (Ab-Ag) model system chosen for the development of SHALs consists of Lym-1, a MAb with proven selectivity in non-Hodgkin's lymphoma (NHL) patients and its well-characterized Ag, the β subunit of HLA DR10. Whereas Lym-1 is readily available, the β subunit of HLA-DR10 is not. Native, heterodimeric (α and β subunits) HLA-DR10 can be purified from Raji cells, which are known to overexpress this Ag. Inconsistent homogeneity between preparations of HLA-DR10 solubilized in the presence of detergents prompted us to express a recombinant form of the β subunit of HLA-DR10 in Escherichia coli. Negligible production yields (≤50 μg/L) were achieved by the expression of the full-length protein in a soluble form. By contrast, yields of 240 mg/L were obtained by expressing only the extracellular domain (ED) of the β subunit of HLA-DR10 in an insoluble form (inclusion bodies). The recovery yield of refolded protein was 75{\%}. Circular dichroism (CD) and Lym-1 binding studies indicated that the recombinant ED of the β subunit of HLA-DR10 was properly folded. Therefore, this recombinant protein can be used as a surrogate for native heterodimeric HLA DR10 for the in vitro selection of SHALs and related targeting molecules.",
keywords = "Antibody, HLA-DR, Lymphoma, Radioimmunotherapy, Radioisotope",
author = "Huguette Albrecht and Monique Cosman and Maria Ngu-Schwemlein and Michele Corzett and Curran, {Kena W.} and Cheryl Dolan and Xiangming Fang and DeNardo, {Sally J.} and Denardo, {Gerald L} and Rod Balhorn",
year = "2007",
month = "8",
doi = "10.1089/cbr.2007.375",
language = "English (US)",
volume = "22",
pages = "531--542",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Recombinant expression of the β-subunit of HLA-DR10 for the selection of novel lymphoma targeting molecules

AU - Albrecht, Huguette

AU - Cosman, Monique

AU - Ngu-Schwemlein, Maria

AU - Corzett, Michele

AU - Curran, Kena W.

AU - Dolan, Cheryl

AU - Fang, Xiangming

AU - DeNardo, Sally J.

AU - Denardo, Gerald L

AU - Balhorn, Rod

PY - 2007/8

Y1 - 2007/8

N2 - Selective high-affinity ligands (SHALs) were selected as substitutes for monoclonal antibodies (mAbs) to deliver radioisotopes to malignant tumors. Because a SHAL (5 KD) is considerably smaller in comparison to an antibody (150 KD), a significant therapeutic index (TI) enhancement for radioimmunotherapy (RIT) is anticipated. The antibody-antigen (Ab-Ag) model system chosen for the development of SHALs consists of Lym-1, a MAb with proven selectivity in non-Hodgkin's lymphoma (NHL) patients and its well-characterized Ag, the β subunit of HLA DR10. Whereas Lym-1 is readily available, the β subunit of HLA-DR10 is not. Native, heterodimeric (α and β subunits) HLA-DR10 can be purified from Raji cells, which are known to overexpress this Ag. Inconsistent homogeneity between preparations of HLA-DR10 solubilized in the presence of detergents prompted us to express a recombinant form of the β subunit of HLA-DR10 in Escherichia coli. Negligible production yields (≤50 μg/L) were achieved by the expression of the full-length protein in a soluble form. By contrast, yields of 240 mg/L were obtained by expressing only the extracellular domain (ED) of the β subunit of HLA-DR10 in an insoluble form (inclusion bodies). The recovery yield of refolded protein was 75%. Circular dichroism (CD) and Lym-1 binding studies indicated that the recombinant ED of the β subunit of HLA-DR10 was properly folded. Therefore, this recombinant protein can be used as a surrogate for native heterodimeric HLA DR10 for the in vitro selection of SHALs and related targeting molecules.

AB - Selective high-affinity ligands (SHALs) were selected as substitutes for monoclonal antibodies (mAbs) to deliver radioisotopes to malignant tumors. Because a SHAL (5 KD) is considerably smaller in comparison to an antibody (150 KD), a significant therapeutic index (TI) enhancement for radioimmunotherapy (RIT) is anticipated. The antibody-antigen (Ab-Ag) model system chosen for the development of SHALs consists of Lym-1, a MAb with proven selectivity in non-Hodgkin's lymphoma (NHL) patients and its well-characterized Ag, the β subunit of HLA DR10. Whereas Lym-1 is readily available, the β subunit of HLA-DR10 is not. Native, heterodimeric (α and β subunits) HLA-DR10 can be purified from Raji cells, which are known to overexpress this Ag. Inconsistent homogeneity between preparations of HLA-DR10 solubilized in the presence of detergents prompted us to express a recombinant form of the β subunit of HLA-DR10 in Escherichia coli. Negligible production yields (≤50 μg/L) were achieved by the expression of the full-length protein in a soluble form. By contrast, yields of 240 mg/L were obtained by expressing only the extracellular domain (ED) of the β subunit of HLA-DR10 in an insoluble form (inclusion bodies). The recovery yield of refolded protein was 75%. Circular dichroism (CD) and Lym-1 binding studies indicated that the recombinant ED of the β subunit of HLA-DR10 was properly folded. Therefore, this recombinant protein can be used as a surrogate for native heterodimeric HLA DR10 for the in vitro selection of SHALs and related targeting molecules.

KW - Antibody

KW - HLA-DR

KW - Lymphoma

KW - Radioimmunotherapy

KW - Radioisotope

UR - http://www.scopus.com/inward/record.url?scp=34548619650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548619650&partnerID=8YFLogxK

U2 - 10.1089/cbr.2007.375

DO - 10.1089/cbr.2007.375

M3 - Article

C2 - 17803448

AN - SCOPUS:34548619650

VL - 22

SP - 531

EP - 542

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 4

ER -